Psoriatic Arthritis News

While biologic therapy persistence rates were generally low at 3 years, interleukin-17 inhibitors were generally more persistent than tumor necrosis factor inhibitors in both psoriasis and psoriatic arthritis, according to a study.

Patients with psoriatic arthritis or ankylosing spondylitis who received once daily upadacitinib 15 mg experienced improvements in pain measures through 1 year, according to data published in RMD Open.

Joint replacement in patients with inflammatory arthritis is often beset with pitfalls like disease flares and infectious complications, and up until recently, the emergence new treatments were rendering the current guidelines outdated.

Rilzabrutinib induced rapid and durable clinical activity in previously treated patients with immune thrombocytopenia, according to results of a phase 1/phase 2 clinical trial published in The New England Journal of Medicine.

The National Psoriasis Foundation COVID-19 Task Force has updated its guidelines to recommend a second booster shot for some patients with psoriasis or psoriatic arthritis.

Deucravacitinib, a TYK2 inhibitor, was well-tolerated and superior to placebo in improving ACR20 response among patients with psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.

Patients with rheumatic and musculoskeletal diseases should engage in both aerobic and strengthening exercises, aiming for at least moderate intensity, according to new EULAR recommendations.

March is Autoimmune Awareness Month, and rheumatology organizations have been using their reach and influence on social media sites to spread the word and help patients with autoimmune diseases find community.

Tofacitinib for psoriatic arthritis is efficacious in most patient-reported and clinical endpoints over time, and shows shorter initial and meaningful response times versus switching from placebo to the drug at month 3, noted researchers.

The American College of Rheumatology and the American Association of Hip and Knee Surgeons have released updated recommendations for the perioperative management of antirheumatic medication in patients undergoing hip and knee arthroplasty.